Медико-биологический
информационный портал
для специалистов
 
Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г.  2022 г.  2023 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 19, Art. 54 (pp. 729-742)    |    2018       
»

Efficiency of glycopyrronium bromide in the complex treatment of chronic obstructive pulmonary disease of a stable course at the real clinical practice
Sharova N.V., Shulenin K.S., Cherkashin D.V., Grishaev S.L., Kutelev G.G.

S.M. Kirov Military Medical Academy, Saint Petersburg, Russia



Brief summary

Оbjective: The aim of the study was to evaluate the clinical and functional efficacy of the long - acting anticholinergic drug glycopyrronium bromide at a dose of 50 ?g per day as part of the complex 28-day therapy of chronic obstructive pulmonary disease (COPD) of a stable course in comparison with tiotropium bromide 5 ?g in real clinical practice. Material and methods: 116 patients with stable COPD of varying degrees of functional (GOLD I-IV) and clinical disorders were examined. Against the background of using glycopyrronium is achieved a significant (n = 60, p < 0.05) decrease in the severity of dyspnea mMRC (-0,71?0,15 points) and CAT (-3,6? 0,69 points), increased tolerance to physical stress, reducing the severity of obstruction, comparable with those in patients, using tiotropium. Obtained result: Bronchodilation effect in 60 minutes after the first use of glycopyrronium is significant (p < 0.01) it exceeded bronchodilation by tiotropium and remained stable on the 28th day of management. Δ FEV1 during therapy with glycopyrronium was dependent on the reversibility of bronchial obstruction during the acute test with the glycopyrronium and was most pronounced in patients not receiving basic therapy on an ongoing basis that allows us to consider a positive bronchodilation test with the glycopyrronium as an individual criterion in the selection of patients for prescribing at the start of treatment of COPD.


Key words

chronic obstructive pulmonary disease, dyspnea, bronchial obstruction, glycopyrronium bromide, tiotropium bromide





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Global Strategy for the Diagnosis, Management and Prevention of COPD (2017). Aviable et: http://goldcopd.org gold-2017-global-strategy-diagnosis-management-prevention-copd (accessed 23 march 2017).


1. Arhipov V.V. Klinicheskaya farmakologiya antiholinergicheskih preparatov / V.V. Arhipov // Prakticheskaya pylmonologiya - 2014. - ?2. - S.32-39.


2. Aisanov Z.R. Nacionalnie klinicheskie rekomendacii po diagnostike i lecheniu hronicheskoi obstryktivnoi bolezni legkih: algoritm prinyatiya klinicheskih reshenii / Z.R. Aisanov i [dr.] // Pylmonologiya. - 2017.- T. 27, ? 1. - S. 13-20.


3. Kazancev V.A. Dvoinaya bronhodilataciya v terapii hronicheskoi obstryktivnoi bolezni legkih stabilnogo techeniya / V.A Kazancev [i dr.] // Vestnik Rossiiskoi Voenno-medicinskoi akademii. - 2016. - T. 56, ?4. - S.228-234.


4. D?Urzo A. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial / A.D?Urzo [et al.] // Respir. Res. - 2011. - Vol. 12, ? 156. - P. 2-13.


5. D'Urzo A. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies /A. D'Urzo [et al.] // Curr. Med. Res. Opin. - 2014. - Vol. 30, ?3. - P.493-508.


6. Jones P.W. Minimal Clinically Important Differences in Pharmacological Trials / P.W. Jones [et al.] // American Journal of Respiratory and Critical Care Medicine. - 2014. -Vol. 189. - P. 250-255.


7. Chapman K.R. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study / K.R. Chapman [et al.] // BMC Pulm. Med. - 2014. - Vol. 14. - P. 4-15.


8. Kerwin E. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study / E. Kerwin [et al.] // Eur. Respir. J. - 2012. - Vol. 40. - P. 1106-1114.


9. Vincken W. Efficacy and safety of co administration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study / W. Vincken [et al.] // Int. J. Chron. Obstruct. Pulmon. Dis. - 2014. - Vol. 9. - P. 215-228.


10. Avdeev S.N. Glikopirroniya bromid: klinicheskaya effektivnost i bezopasnost pri HOBL (obzor klinicheskih issledovanii) / S.N. Avdeev, S.U. Chikina // Medicinskii Sovet. - 2015. - N16. - C. 12-19.


11. Titova O.N. Glikopirroniya bromid v terapii hronicheskoi obstryktivnoi bolezni legkih stabilnogo techeniya / O.N. Titova // RMJ. - 2017. - N11. - S. 808-814.


12. Negoda S.V. Sovremennie vozmojnosti terapii HOBL v Rossii: ot klinicheskih rekomendacii k realnoi praktik / S.V. Negoda [i dr.] // Effektivnaya farmakoterapiya. - 2017. - N2. - C.24-32.


13. Zagidyllin N.Sh. Vliyanie kombinirovannoi terapii indakaterolom i glikopirroniya bromidom na sostoyanie respiratornoi i serdechno-sosydistoi sistem y pacientov s hronicheskoi obstryktivnoi boleznu legkih / N.Sh. Zagidyllin, R.H. Zylkarneev, U.F. Safina // Pylmonologiya. - 2015. - T. 25, N6. - S. 747-752.


14. Trofimenko I.N. Bronhoprotektivnii effekt glikopirroniya bromida / I.N. Trofimenko // Medicinskii sovet. - 2017. - N 8. - S. 8-12.


15. Tryshina E.U. Klinicheskii opit primeneniya glikopirroniya bromida y bolnih s sochetanie hronicheskoi obstryktivnoi bolezni legkih i bronhialnoi astmi / E.U. Tryshina, E.M. Kostina // Sovremennie problemi nayki i obrazovaniya. - 2017. - N 3.


16. Vakyrova N.V. Ocenka effektivnosti aklidiniya bromida y bolnih professionalnoi hronicheskoi obstryktivnoi boleznu legkih / N.V. Vakyrova, T.A. Azovskovaya // Nayka i innovacii v medicine. - 2017. - T.2, N6. - S. 26-29.


17. Sharova N.V. «Spiriva Respimat» v kompleksnoi terapii hronicheskoi obstryktivnoi bolezni legkih/ N.V. Sharova, G.G. Kytelev, D.V. Cherkashin // Vestnik Rossiiskoi Voenno-medicinskoi Akademii. - 2015. - T.51, N3. - S. 67-71.


18. Sharova N.V. Znachenie pokazatelei modificirovannogo bronhodilatacionnogo testa s glikopirroniem dlya viyavleniya obratimosti bronhialnoi obstrykcii y bolnih hronicheskoi obstryktivnoi boleznu legkih / N.V. Sharova [i dr.] // Klinicheskaya medicina. - 2018. - T.96, N.2. - S.158-164.


19. Chychalin A.G. Federalnie klinicheskie rekomendacii Rossiiskogo respiratornogo obshestva po ispolzovaniu metoda spirometrii / A.G. Chychalin [i dr.] // Pylmonologiya. - 2014. - N6. - S. 11-24.


20. Rebrova O.U. Statisticheskii analiz medicinskih dannih. Primenenie paketa prikladnih programm STATISTICA. - M., MediaSfera. - 2002. - 312 s.


21. Arhipov V.V. Chastota vstrechaemosti otdelnih fenotipov hronicheskoi obstryktivnoi bolezni legkih v Rossiiskoi Federacii, ih harakteristika i podhodi k lecheniu/ V.V. Arhipov [i dr.] // Prakticheskaya pylmonologiya. - 2016. - N3. - S. 20-25.


22. Hanania N.A. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial / N.A. Hanania [et al.] // Respir.Res. - 2011. - Vol. 12, N 6. - P. 1-11.


23. Avdeev S.N. Maksimalnaya bronhodilataciya so starta terapii hronicheskoi obstryktivnoi bolezni legkih: vliyanie na techenie zabolevaniya / S.N. Avdeev, Z.R. Aisanov // Pylmonologiya. - 2016. - T.26, N5. - S 604-609.


24. Marin J.M. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the morning) / J.M. Marin [et al.] // Int. J. Chron. Obstruct. Pulmon. Dis. - 2016. - Vol. 11. - P. 1425-1434.


25. Kon S.S. Minimum clinicall yimportant difference for the COPD Assessment Test: aprospectiveanalysis / S.S. Kon [et al.] // Lancet Respir Med. - 2014. - N 2. - P.195-203/


26. La Force C. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study / C. La Force [et al.] // Int. J. Chron. Obstruct. Pulmon. Dis. - 2016. - N 8. - P. 233-243.


27. Rogliani P. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi / P. Rogliani [et al.] // Eur. J. Pharmacol. - 2015. - Vol. 761. - P.383-390.


28. Vogelmeier C.F. Efficacy and safety of direct switch to indacaterol/glycopypyrronium in patients with moderate COPD: the CRYSTAL open label randomised trial Respiratory Research / C.F. Vogelmeier [et al.] // Respiratory research. - 2017. -Vol. 18, N 1. - P.2-9.





Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100